Image source: Shutterstock

Highlights

• Amplia's ACCENT trial hits key efficacy threshold with 15 confirmed partial responses

• Trial shows narmafotinib + chemotherapy outperforms chemotherapy alone

• Top-line data expected Q3 2025; ATX shares jump 58% to 8.7 cents